The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of mid-treatment FDG-PET adaptive, individualized radiation therapy plus concurrent chemotherapy in patients with non-small cell lung cancer (NSCLC).
Fengming Kong
No relevant relationships to disclose
Randall K Ten Haken
No relevant relationships to disclose
Matthew J Schipper
No relevant relationships to disclose
James Hayman
No relevant relationships to disclose
Nithya Ramnath
No relevant relationships to disclose
Khaled Aref Hassan
No relevant relationships to disclose
Martha Matuszak
No relevant relationships to disclose
Timothy Ritter
No relevant relationships to disclose
Nan Bi
No relevant relationships to disclose
Weili Wang
No relevant relationships to disclose
Mark Orringer
No relevant relationships to disclose
Kemp Bailey Cease
No relevant relationships to disclose
Theodore Steven Lawrence
No relevant relationships to disclose
Gregory Peter Kalemkerian
No relevant relationships to disclose